TY  - CHAP
M1  - Book, Section
TI  - Myelodysplastic Syndromes
A1  - Damon, Lloyd E.
A1  - Andreadis, Charalambos Babis
A2  - Papadakis, Maxine A.
A2  - McPhee, Stephen J.
A2  - Rabow, Michael W.
A2  - McQuaid, Kenneth R.
PY  - 2022
T2  - Current Medical Diagnosis & Treatment 2022
AB  - Key  Clinical  Updates  in  Myelodysplastic  SyndromesA  novel  agent,  luspatercept,  has  been  developed  to  target  signaling  via  the  SMAD2–SMAD3  pathway  which  is  constitutively  increased  in  the  bone  marrow  cells  of  patients  with  MDS  and  ineffective  erythropoiesis.In  a  randomized  study,  luspatercept  induced  transfusion  independence  in  38%  of  lower-risk  MDS  patients  who  did  not  respond  to  growth  factor  therapy  compared  to  13%  in  the  placebo  arm.  
SN  - 
PB  - McGraw-Hill Education
CY  - New York, NY
Y2  - 2024/04/19
UR  - accessmedicine.mhmedical.com/content.aspx?aid=1184166123
ER  -